+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hereditary Testing - Global Strategic Business Report

  • PDF Icon

    Report

  • 282 Pages
  • October 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 5302540
The global market for Hereditary Testing was valued at US$6.1 Billion in 2025 and is projected to reach US$9 Billion by 2032, growing at a CAGR of 5.7% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Hereditary Testing Market - Key Trends and Drivers Summarized

Why Is Hereditary Testing Revolutionizing Personalized Medicine?

Hereditary testing has become a transformative tool in modern medicine, enabling the detection of genetic mutations associated with inherited diseases and conditions. It plays a critical role in diagnosing genetic disorders, guiding personalized treatment plans, and informing patients of their potential risk of passing on genetic traits to their offspring. Hereditary testing encompasses a wide range of applications, including cancer risk assessment, reproductive health, and cardiovascular diseases. As the cost of genetic sequencing continues to decrease, hereditary testing has become more accessible, empowering individuals with valuable insights into their health and enabling early intervention or preventive care measures. With advancements in genomic science, hereditary testing is now a cornerstone of personalized medicine, providing tailored healthcare solutions based on individual genetic profiles.

How Are Technological Advancements Expanding the Hereditary Testing Market?

The hereditary testing market has been revolutionized by advancements in genetic sequencing technologies, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR). These technologies allow for faster, more accurate, and cost-effective genetic analysis, making it easier to identify mutations across a broad range of genes. The development of direct-to-consumer (DTC) genetic testing kits has further expanded the market, enabling individuals to access hereditary testing without the need for a healthcare provider. Moreover, the integration of bioinformatics tools and AI has enhanced the ability to interpret complex genetic data, providing deeper insights into gene-environment interactions and hereditary risks. These innovations are also improving the accuracy and reliability of prenatal and preimplantation genetic testing, ensuring safer reproductive health decisions.

How Are Market Segments Shaping the Hereditary Testing Industry?

Test types include predictive testing, carrier testing, prenatal testing, and newborn screening, with predictive testing being the largest segment due to its widespread use in assessing the risk of developing inherited conditions such as cancer. Applications of hereditary testing range from oncology and cardiology to reproductive health and rare genetic disorders. Oncology represents the most significant application, particularly in detecting BRCA1/BRCA2 mutations linked to breast and ovarian cancers. The end-use segment includes hospitals, diagnostic laboratories, and direct-to-consumer testing services, with diagnostic laboratories holding the largest share due to their advanced genetic testing capabilities and infrastructure.

What Factors Are Driving the Growth in the Hereditary Testing Market?

The growth in the hereditary testing market is driven by several factors, including increasing awareness of genetic disorders, technological advancements in genetic sequencing, and the growing demand for personalized medicine. Rising awareness among consumers about the importance of genetic testing for early disease detection and prevention is fueling demand for hereditary testing services. Technological innovations, particularly in next-generation sequencing (NGS), have made hereditary testing faster, more accurate, and affordable, expanding its accessibility to a broader population. The growing focus on personalized healthcare solutions, where treatment plans are tailored based on individual genetic profiles, is further boosting market growth. Additionally, the expansion of direct-to-consumer genetic testing services has democratized access to hereditary testing, allowing individuals to proactively manage their health based on genetic insights.

Report Scope

The report analyzes the Hereditary Testing market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Test Type (Preimplantation Genetic Diagnosis & Screening, Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests, Genetic Tests, Newborn Genetic Screening, Other Test Types); Technology (Molecular, Cytogenetic, Biochemical).
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Preimplantation Genetic Diagnosis & Screening segment, which is expected to reach US$3.4 Billion by 2032 with a CAGR of a 6.5%. The Non-Invasive Prenatal Testing (NIPT) & Carrier Screening Tests segment is also set to grow at 5.7% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $1.7 Billion in 2025, and China, forecasted to grow at an impressive 8.8% CAGR to reach $1.9 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Hereditary Testing Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Hereditary Testing Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Hereditary Testing Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Agilent Technologies, Inc., CENTOGENE N.V., CooperSurgical, Inc., F. Hoffmann-La Roche Ltd, Fulgent Genetic, Inc. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Hereditary Testing market report include:

  • Agilent Technologies, Inc.
  • CENTOGENE N.V.
  • CooperSurgical, Inc.
  • F. Hoffmann-La Roche Ltd
  • Fulgent Genetic, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Medgenome
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Quest Diagnostics Incorporated
  • Sophia Genetics
  • Thermo Fisher Scientific, Inc.
  • Twist Bioscience

What Sets This Report Apart From Others?

  • Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
  • Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
  • Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
  • Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
  • Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
  • Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, our reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Agilent Technologies, Inc.
  • CENTOGENE N.V.
  • CooperSurgical, Inc.
  • F. Hoffmann-La Roche Ltd
  • Fulgent Genetic, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Medgenome
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Quest Diagnostics Incorporated
  • Sophia Genetics
  • Thermo Fisher Scientific, Inc.
  • Twist Bioscience

Table Information